Faster Diagnosis

Faster Diagnosis

Faster diagnosis through smarter bladder cancer pathway triage.

Uromonitor® supports clinicians with molecular urine testing that can help prioritise patients who need cystoscopy sooner and support faster escalation where clinically appropriate.

Discuss Implementation View Clinical Evidence
Modern molecular diagnostics laboratory with PCR testing equipment
Urine sample Non-invasive
dPCR signal Molecular result
Risk review Clinical context
Cystoscopy Prioritised

The issue is not just testing. It is pathway pressure.

Most bladder cancer cystoscopy demand comes from surveillance, not first diagnosis. Around 75% of bladder cancers are non-muscle-invasive, and these patients often need repeated follow-up for years. Surveillance may account for around 70% of bladder cancer-related cystoscopy activity.

Cystoscopy remains essential, but many surveillance procedures are negative and use scarce clinical capacity. Uromonitor adds non-invasive molecular evidence earlier in the surveillance pathway, helping clinicians identify low-risk patients who may not need immediate cystoscopy, while positive or higher-risk cases are escalated.

The result is fewer avoidable surveillance cystoscopies, more capacity for urgent suspected cancer referrals, and a better patient experience.

PCR plate and molecular diagnostics testing equipment
01

Molecular urine testing

A non-invasive urine sample can provide clinically useful molecular information before immediate invasive investigation is required.

02

Cystoscopy prioritisation

Positive molecular findings can support faster escalation towards cystoscopy for patients with greater clinical or molecular concern.

03

Capacity released for higher-risk patients

Lower-risk surveillance episodes may be managed more intelligently where clinical governance and test results support that approach.

Pathway Model

A clearer route from urine sample to clinical decision.

The strongest use case is a governed pathway where Uromonitor supports decision-making alongside recurrence risk, cytology and clinician judgement.

1

Recurrence risk review

Clinical history and risk profile guide the first pathway decision.

2

Urine sample

Suitable patients provide urine for cytology and/or molecular testing.

3

Uromonitor result

Molecular findings add another signal into pathway triage.

4

Clinical decision

Results are interpreted alongside cytology, history and judgement.

5

Prioritised cystoscopy

Patients with higher concern can be moved faster to investigation.

Impact

Faster diagnosis comes from smarter capacity use.

The value is not simply that Uromonitor is a urine test. The value is pathway design: helping services identify who should move faster towards cystoscopy while reducing unnecessary pressure from lower-risk surveillance episodes where clinically appropriate.

Earlier decision support Molecular results can support earlier triage decisions in the bladder cancer surveillance pathway.
Better queue prioritisation Cystoscopy capacity can be focused on patients with greater clinical or molecular concern.
Same-sample potential Reflex testing can support cleaner workflow where local protocols allow use of the same urine sample.
Governance retained Results remain part of a clinician-led pathway, not a standalone consumer screening model.
Clinical Governance

Designed to support clinical judgement, not replace it.

Uromonitor should be positioned as an adjunct to cystoscopy and cytology within a governed clinical pathway. The result should support escalation, reassurance or continued surveillance decisions where clinically appropriate.

✓ Clear patient-selection criteria and escalation rules.
✓ Laboratory workflow, quality control and reporting governance.
✓ Clinical interpretation alongside recurrence risk, cytology and history.
✓ Audit of pathway impact, cystoscopy use and clinical outcomes.
NHS laboratory workflow showing sample handling and clinical governance

Discuss faster pathway adoption.

Speak to Progen Diagnostics about how Uromonitor could support bladder cancer surveillance, cystoscopy prioritisation and faster diagnostic pathway decisions.

Discuss Implementation